Duke Energy Corp vs Eli Lilly And Co — how do they compare? Duke Energy Corp trades at $125.65 (market cap $98.52B), while Eli Lilly And Co trades at $1,144.54 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 10.5× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| DUK | LLY | |
|---|---|---|
Market Cap | $98.52B | $1.03T |
Sector | Utilities | Health |
52-Week High | $133.46 | $1.24K |
52-Week Low | $113.99 | $625.65 |
Enterprise Value | $188.56B | $1.07T |
Dividend Yield | 3.37% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $126.86, up 1.1% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows stable revenue growth, with 2025 revenue reaching $32.24B and net income of $4.97B, supported by a 15.49% net margin. Recent news highlights a dividend increase to $1.085 per share and strong institutional interest, with 37.5% of analysts rating it a Buy.
The outlook remains positive with a consensus price target of $136.60, offering ~7.7% upside. Risks include high debt levels (46.17% debt-to-asset ratio) and regulatory pressures, but the company's defensive utility profile and dividend reliability provide stability amid market volatility.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →